Entrada Days Payables Outstanding vs Price To Sales Ratio Analysis
| TRDA Stock | USD 19.37 0.33 1.73% |
Entrada Therapeutics financial indicator trend analysis is much more than just examining Entrada Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entrada Therapeutics is a good investment. Please check the relationship between Entrada Therapeutics Days Payables Outstanding and its Price To Sales Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
Days Payables Outstanding vs Price To Sales Ratio
Days Payables Outstanding vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entrada Therapeutics Days Payables Outstanding account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong relationship.
The correlation between Entrada Therapeutics' Days Payables Outstanding and Price To Sales Ratio is 0.71. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Entrada Therapeutics, assuming nothing else is changed. The correlation between historical values of Entrada Therapeutics' Days Payables Outstanding and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Entrada Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Days Payables Outstanding i.e., Entrada Therapeutics' Days Payables Outstanding and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 0.71 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Days Payables Outstanding
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Entrada Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Entrada Therapeutics sales, a figure that is much harder to manipulate than other Entrada Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Entrada Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entrada Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.The current year's Enterprise Value is expected to grow to about 569.3 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 2.8M | 3.0M | Interest Income | 2.6M | 15.2M | 16.0M |
Entrada Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Entrada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.